Astria Therapeutics, Inc. (ATXS)
Largest Insider Buys in Sector
ATXS Stock Price History Chart
ATXS Stock Performance
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, …
Insider Activity of Astria Therapeutics, Inc.
Over the last 12 months, insiders at Astria Therapeutics, Inc. have bought $34.59M and sold $247,303 worth of Astria Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Astria Therapeutics, Inc. have bought $17.2M and sold $247,303 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (director) — $518.81M.
The last purchase of 2,481,350 shares for transaction amount of $30M was made by PERCEPTIVE ADVISORS LLC (director) on 2024‑02‑01.
List of Insider Buy and Sell Transactions, Astria Therapeutics, Inc.
| 2024-04-01 | Sale | Chief Medical Officer | 10,000 0.0183% | $13.59 | $135,939 | -18.58% | ||
| 2024-02-01 | director | 2.48M 5.6893% | $12.09 | $30M | -16.45% | |||
| 2024-01-29 | Sale | Chief Medical Officer | 9,200 0.0208% | $11.15 | $102,552 | -4.61% | ||
| 2024-01-26 | Sale | Chief Medical Officer | 800 0.0022% | $11.02 | $8,812 | +5.40% | ||
| 2023-12-21 | director | 740,000 2.0257% | $6.20 | $4.59M | +79.04% | |||
| 2023-10-16 | director | 1.07M 3.9128% | $6.51 | $7M | +53.54% | |||
| 2022-12-19 | director | 908,265 6.1619% | $11.01 | $10M | -10.50% | |||
| 2021-11-19 | Chief Commercial Officer | 100 0.0008% | $6.70 | $670 | -6.97% | |||
| 2015-06-30 | 10 percent owner | 391,090 2.5125% | $12.00 | $4.69M | -41.69% | |||
| 2015-06-30 | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | ||||
| 2015-06-30 | 10 percent owner | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | |||
| 2015-06-30 | 10 percent owner | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | |||
| 2015-06-30 | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | ||||
| 2015-06-30 | director | 258,776 1.6625% | $12.00 | $3.11M | -41.69% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | director | 4873721 8.6375% | $11.79 | 4 | 0 | <0.0001% |
| SVLSF V, LLC | 10 percent owner | 2798528 4.9597% | $11.79 | 1 | 0 | |
| GALAKATOS NICHOLAS | 2752488 4.8781% | $11.79 | 1 | 0 | ||
| Clarus Lifesciences II, L.P. | 10 percent owner | 2752488 4.8781% | $11.79 | 1 | 0 | |
| MedImmune Ventures, Inc. | 10 percent owner | 1632652 2.8935% | $11.79 | 1 | 0 |
Institutional Investor Ownership
| Perceptive Advisors | $91.25M | 11.81 | 6.49M | +61.97% | +$34.91M | 0.06 | |
| Tcg Crossover Management Llc | $74.3M | 9.61 | 5.28M | New | +$74.3M | 0.12 | |
| RA Capital Management, L.P. | $62.12M | 8.04 | 4.41M | New | +$62.12M | 0.06 | |
| Fidelity Investments | $60.79M | 7.87 | 4.32M | -10.07% | -$6.81M | <0.01 | |
| Vr Adviser Llc | $50.79M | 6.57 | 3.61M | +11.87% | +$5.39M | 2.47 |